Научная литература
booksshare.net -> Добавить материал -> Медицина -> Джордж А.Г. -> "Анестезия и педиатрия" -> 96

Анестезия и педиатрия - Джордж А.Г.

Джордж А.Г. Анестезия и педиатрия — М.: Медицина, 2003. — 1192 c.
ISBN 5-225-03821-2
Скачать (прямая ссылка): anesteziyavpedeatrii2003.djvu
Предыдущая << 1 .. 90 91 92 93 94 95 < 96 > 97 98 99 100 101 102 .. 1012 >> Следующая

154. Ward A, Chaffman MO, Sorkin EM: Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 32:130, 1986
155. Alien GC, Cattran CB, Peterson RG, Lalande M: Plasma levels of dantrolene following oral administration in malignant hyperthermia susceptible patients. Anesthesiology 69:900, 1988
156. Larman J, McZeod M E, Strong HA: Pharmacokinetics of intravenous dantrolene in children. Anesthesiology 70:625, 1989
157. Potney JW, Bianchi CP: Site of action of dantrolene in frog sartorius muscle. J Pharmacol Exp Ther 189:202,
1974
158. Kurihara T, Brooks JE: Excitation-contraction uncoupling. The effect of hyperosmolar solution and dantrolene sodium on mammalian muscle in vitro. Arch Neurol 32:92, 1975
159. Morgan KG, Bryant SH: The mechanism of action of dantrolene sodium. J Pharmacol Exp Ther 201:138, 1977
160. Allen P, Lopez JR, Jones Detal: Measurements of (CaI4Ji in skeletal muscle of malignant hyperthermic swine. An-esthesiology 63A268, 1985
161. Van Winkle WB: Calcium release from skeletal muscle sarcoplasmic reticulum: site of action of dantrolene sodium? Science 193:1130, 1976
162. Roewer N, Kuck KH, Nienaber CH et al: Electrophysio-logic effects of intravenous dantrolene on dog hearts. Anesthesiology 61 A254, 1984
163. Roewer N, Rumbergar E, Schulte am Esch J: Effects of dantrolene on excitation-contraction coupling in isolated heart muscle. Anesthesiology 6I:A255, 1984
164. Lynch С III, Durbin CG Jr. Fisher NA et al: Effects of dantrolene and verapamil on atrioventricular conduction and cardiovascular performance in dogs. Anesth Analg 66:252, 1986
165. Saltzman LS, Kates RA, Norfleet EA et al: Hemodynamic inseractions of diltiazem-dantrolene and nifedipine-dant-rolene. Anesthesiology 6|:AI I, 1984
166. Rubin AS, Zablocki AD: Hyperkalemia, verapamil, and dantrolene. Anesthesiology 66:246, 1987
167. San Juan AC, Wong КС, Port D: Hyperkalemia after dantrolene and verapamil-dantrolene administration in dogs. Anesth Analg 67:759, 1988
168. Schneider R, Mitchall D: Dantrolene hepetitis. JAMA 235:1590, 1976
169. Roy S, Francis KT, Bom CK, Hamrick ME: Interaction of dantrolene with the hepatic mixed function oxidase system. Res Co mm un Chem Pathol Pharmacol 27:507, 1980
170. Abernathy CO, Utili R, Zimmerman HJ, Ezekiel M: The effects of dantrolene sodium on excretory function in the isolated perfused rat liver. Toxicol Appl Pharmacol 44:441, 1978
171. Francis KT, Hamrick ME: Dantrolene inhibition of the hepatic mixed function oxidase system. Res Commun Chem Pathol Pharmacol 23:69, 1979
172. Petusevsky ML, Faling U, Rocklin RE et al: Pleuropericardial reaction to treatment with dantrolene. JAMA 242:2772, 1979
173. Rosenblatt R, Tollman RD Jr, Weaver J, Wang Y: Dant-rolene potentiates the toxicity of bupivacaine. Anesthesiology 61 :A209, 1984
174. Watson CB, Reierson N, Norfleet EA: Clinically significant muscle weakness induced by oral dantrolene sodium prophylaxis for malignant hyperthermia. Anesthesiology 65:312, 1986
175. Wingard DW: Controversial regarding the prophylactic use of dantrolene for malignant hyperthermia (letter). Anesthesiology 58:489, 1983
176. Dershwitz M, Srtter FA: Azumolene reverses episodes of malignant hyperthermia in susceptible swine. Anesth Analg 70:253, 1990
177. Harrison GG, Morrell DF: Response of mhs swine to I. V. infusion of lignocaine and bupivacaine. Br J Anaesth 52:385, 1980
178. Wingard DW, Bobko S: Failure of lidocaine to trigger porcine malignant hyperthermia. Anesth Analg 58:99, 1979
179. Andragna MG: Medical protocol by habit — the avoidance of amide local anesthetics in malignant hyperthermia susceptible patients. Anesthesiology 62:99, 1985
180. Britt BA: Malignant hyperthermia. Can Anaesth Soc J 32:666. 1985
181. Honda N, Konno K, Itohda Y et al: Malignant hyperthermia and althesin. Can Anaesth Soc J 24:514, 1977
182. Suresh MS, Nelson ТЕ: Malignant hyperthermia: is eto-midate safe? Anesth Analg 64:420. 1985
183. Ellis FR, Clark IMC, Appleyard TN, Dinsdale RCW: Malignant hyperpyrexia induced by nitmus oxide and treated with dexamethasone. Br Med J 4:270, 1974
184. Fitzgibbons DC: Malignant hyperthermia following pre-operative oral administration of dantrolene. Anesthesiology 54:73, 1981
185. Dolan PF: Dontrolene and malignant hyperthermia (letter). Anesthesiology 57:246, 1982
186. Carr AS. Lerman J, Cunliffe M, et al: Incidence of malignant hyperthermia reactions in 2,214 patients undergo-jag muscle biopsy. Can J Anaesth 42:281, 1995
187. La гас h MG: Standardization of the caffeine halothane muscle contracture test. Anesth Analg 69:511, J989
188. Islander G, Twetman ER: Comparison between the European and North American protocols for diagnosis of ma-lignent hyperthermia susceptibility in humans. Anesth An* alg 88:1155, 1999
189. Nelson ТЕ, Flewellen EH, Gloyna DF: Spectrum of susceptibility to malignant hyperthermia — diagnostic dilemma. Anesth Analg 62:545, 1983
Предыдущая << 1 .. 90 91 92 93 94 95 < 96 > 97 98 99 100 101 102 .. 1012 >> Следующая

Реклама

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed

Есть, чем поделиться? Отправьте
материал
нам
Авторские права © 2009 BooksShare.
Все права защищены.
Rambler's Top100

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed